Talk:Biomarker

This is the talk page for discussing improvements to the Biomarker article.
This is not a forum for general discussion of the article's subject.

Put new text under old text. Click here to start a new topic.
New to Wikipedia? Welcome! Learn to edit; get help.

Article policies

Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL

Molecular Biology: MCB

	This article is within the scope of WikiProject Molecular Biology, a collaborative effort to improve the coverage of Molecular Biology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.Molecular BiologyWikipedia:WikiProject Molecular BiologyTemplate:WikiProject Molecular BiologyMolecular Biology articles
???	This article has not yet received a rating on the importance scale.
	This article is supported by the Molecular and Cell Biology task force (assessed as Mid-importance).

Medicine Low‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Low	This article has been rated as Low-importance on the project's importance scale.

Wiki Education Foundation-supported course assignment

This article was the subject of a Wiki Education Foundation-supported course assignment, between 23 August 2021 and 10 December 2021. Further details are available on the course page. Student editor(s): Rnelson2021.

Above undated message substituted from Template:Dashboard.wikiedu.org assignment by PrimeBOT (talk) 18:02, 17 January 2022 (UTC)[reply]

Wiki Education Foundation-supported course assignment

This article was the subject of a Wiki Education Foundation-supported course assignment, between 7 January 2020 and 20 March 2020. Further details are available on the course page. Student editor(s): Redheadweek13.

Above undated message substituted from Template:Dashboard.wikiedu.org assignment by PrimeBOT (talk) 15:47, 16 January 2022 (UTC)[reply]

Biomarker versus Bioindicator

If there is a difference between these two terms, please could someone explain it? --RichardVeryard 10:07, 31 August 2007 (UTC)[reply]

and Biosignature as well --RichardVeryard 13:02, 5 September 2007 (UTC)[reply]

A bioindicator is an organism or biological response.

biomarker is a characteristic that is objectively measured and evaluated as an indicator of normal biologic processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.

Substance?

Is a biomarker necessarily a substance? For example, [Biomonitoringinfo.org/glossary] says:

Indicator signaling an event or condition in a biological system or sample and giving a measure of exposure, effect, or susceptibility. As related to biomonitoring, a biomarker is the presence of any substance, or a change in any biological structure or process that can be measured as a result of exposure. Many biomonitoring studies focus on chemical substances or their metabolites as biomarkers.

Biomarker (geology) is defined as a "measureble phenomenon that ...". Other definitions found by searching Google for "define:biomarker" are also more general. -Pgan002 (talk) 05:19, 22 August 2008 (UTC)[reply]

any measurable change in organism. (protein, gene, tracer (ex FDG PET) metabolite, nucleotide, lipid, hormone)

Biomarker disambiguation is needed.

The discussion topics to date point out the need for disambiguation and the development of a usable taxonomy, or functional classifications, of biomarkers by several traits such as field of use, intended purpose, methods employed. The emerging fields of genetics and biochemical assay have pretty much captured the common understanding of the term "biomarker" to mean a "molecular marker" that is used to identify a specific biological condition or state, which leads to confusion when discussing other valid uses of the term "biomarker".

For example, I am currently engaged in the development "bio-signal makers" used to identify specific biological or neurological conditions or states. There are no molecular or chemical processes involved at all, yet "bio-signal biomarkers" are possible that can provide certain disease marker/indicators comparable to some "molecular biomarkers". To avoid confusion we have devised our own unique terminology when writing about or discussing our technology. As time allows I plan to develop a stub in my area of expertise associated with this Biomarker article. --Bitsbear (talk) 04:24, 14 March 2009 (UTC)[reply]

It is unclear to me why a new term is needed, i.e., "bio-signal makers" -- I believe that it is widely accepted that a biomarker is not limited to only "molecules". I would say a biomarker is any 'marker' (i.e. property) that 'marks' a difference in a biological system. Dimo400 (talk) 00:47, 1 May 2009 (UTC)[reply]

I don't really think that a dab treatment of biomarker is needed. The term is in flux, certainly, and not everybody agrees on the specific definition (though there is a broadly accepted definition from the NIH -- I don't recall the specifics right now, but I might be recalling the NCI definition presented in a comment up the page from here), but that is true of a number of fields, such as bioinformatics, computational biology, information science .... There are groups of scientists for whom the "biomarkers are molecular markers" definition is the common understanding, but there is no such across-the-board common understanding. For instance, I am currently working with a group for whom specific EEG phenomena (such as certain evoked potential responses like the P300 or P50 response) serve as biomarkers. This is in the pharmaceutical industry and spans pre-clinical and clinical study development and has been put in practice throughout the pharma industry for particular indications (e.g. Alzheimer's Disease). Therefore, though a "functional classification" of biomarkers would be useful, disambiguation is really not necessary - let's keep the treatment broad. Further, about that "functional classification", we do need to separate the building of the encyclopedia based on existing information from the development of new knowledge. It would not be appropriate to create a functional classification of biomarkers in Wikipedia that does not already exist outside of Wikipedia. In other words, we can report on classifications of biomarkers (and there are several existing schemes for this) but not create one anew based on information gathered here. That is a limitation of creating encyclopedic content. --User:Ceyockey (talk to me) 01:40, 1 May 2009 (UTC)[reply]

Merger proposal

This DAb page was a bad idea. I'm a professional in a field dealing closely with this subject and I find the content confusing. I may try to put some effort into cleaning/merging this when I find time. NickCT (talk) 15:43, 23 December 2009 (UTC)[reply]

Traumatic Brain Injury biomarkers

This section really looks like it was copy pasted from somewhere else. The references are just text in square brackets and not links to the article's own references (and the numbers in brackets go up to 139, while the Wiki article doesn't even have that many), and the paragraph about biomarker attributes mentions "Table 2", which clearly is no part of this Wikipedia article. I think a good candidate is this article. It is a publication that Google returned when searching for fragments from this section (although the full publication text is behind a paywall, so I can't access it) and the first author of the publication is Kevin K. Wang, while the Wiki contribution was made by a user called Wangk111.

Independovirus (talk) 13:46, 21 January 2019 (UTC)[reply]

To add following a revdel

Neurofilament light chain,^[1]^[2] Seppi333 (Insert 2¢) 05:28, 25 January 2019 (UTC)[reply]

References

^ Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, Barro C, Kappos L, Comabella M, Fazekas F, Petzold A, Blennow K, Zetterberg H, Kuhle J (October 2018). "Neurofilaments as biomarkers in neurological disorders". Nature Reviews. Neurology. 14 (10): 577–589. doi:10.1038/s41582-018-0058-z. PMID 30171200. neuroaxonal damage is the pathological substrate of permanent disability in various neurological disorders. ... Here, we review what is known about the structure and function of neurofilaments, discuss analytical aspects and knowledge of age-dependent normal ranges of neurofilaments and provide a comprehensive overview of studies on neurofilament light chain as a marker of axonal injury in different neurological disorders, including multiple sclerosis, neurodegenerative dementia, stroke, traumatic brain injury, amyotrophic lateral sclerosis and Parkinson disease.
^ Thompson AB, Mead SH (December 2018). "Review: Fluid biomarkers in the human prion diseases". Molecular and Cellular Neurosciences. doi:10.1016/j.mcn.2018.12.003. PMID 30529227. The very rapid neurodegeneration of prion disease results in strong signals from surrogate protein markers in the blood that reflect neuronal, axonal, synaptic or glial pathology in the brain: notably the tau and neurofilament light chain proteins.

Copyright problem removed

Prior content in this article duplicated one or more previously published sources. The material was copied from: https://doi.org/10.1080/14737159.2018.1428089. Copied or closely paraphrased material has been rewritten or removed and must not be restored, unless it is duly released under a compatible license. (For more information, please see "using copyrighted works from others" if you are not the copyright holder of this material, or "donating copyrighted materials" if you are.)

For legal reasons, we cannot accept copyrighted text or images borrowed from other web sites or published material; such additions will be deleted. Contributors may use copyrighted publications as a source of information, and, if allowed under fair use, may copy sentences and phrases, provided they are included in quotation marks and referenced properly. The material may also be rewritten, providing it does not infringe on the copyright of the original or plagiarize from that source. Therefore, such paraphrased portions must provide their source. Please see our guideline on non-free text for how to properly implement limited quotations of copyrighted text. Wikipedia takes copyright violations very seriously, and persistent violators will be blocked from editing. While we appreciate contributions, we must require all contributors to understand and comply with these policies. Thank you. Justlettersandnumbers (talk) 22:05, 27 April 2019 (UTC)[reply]

Expansion on Biomarkers: Ethical Debates, usage in Chemistry, new elements to Regulations/Validation, and a section on Usage in Precision Medicine

This is a proposition of several additions to the page. The aim is to critically expand the comprehensiveness of the page with examples on biomarkers usage in chemistry/environmental science with a paragraph on biomarkers role in oil spill cleanup, a section of research within precision medicine with a few narrow examples (mostly on the ability for biomarkers to be multi-omic rather than entirely molecular or genetic), and an expansion to the ethics and issues surrounding biomarker usage and research.

This is a principal emphasis of our (team of two) expansion: 1) To include multi-omic sources in general definition of the research field of biomarkers with examples from literature and publications 2) Capture the new, up to date standards for biomarker validation and regulation, and visit current issues with biomarker research such as validation, HIPAA importance, and ethnicity of participants. 1onicCoval3nt (talk) —Preceding undated comment added 01:31, 17 February 2020 (UTC)[reply]

An addition to the history section of this page, as well as an addition of a "definitions over time" section might benefit this page for readers to familiarize themselves with the history and debate over the meaning of a biomarker. I also propose an addition to the Ecotoxicology section to cite Rachel Carson, the author of Silent Spring as an important person in the field of biomarkers. Also, a blurb about active biomonitoring seems relevant to this topic. Redheadweek13 (talk) 19:38, 18 March 2020 (UTC)[reply]

Wiki Education assignment: Toxicology

This article was the subject of a Wiki Education Foundation-supported course assignment, between 10 August 2022 and 8 December 2022. Further details are available on the course page. Student editor(s): Tdepeyster (article contribs).

— Assignment last updated by Tdepeyster (talk) 18:08, 28 September 2022 (UTC)[reply]

Wiki Education assignment: Advanced Writing Science

This article was the subject of a Wiki Education Foundation-supported course assignment, between 29 August 2022 and 16 December 2022. Further details are available on the course page. Student editor(s): Cedarwaxwing25, Ishkigiizis (article contribs).

— Assignment last updated by Ishkigiizis (talk) 20:13, 12 October 2022 (UTC)[reply]

"Biomaker" listed at Redirects for discussion

The redirect Biomaker has been listed at redirects for discussion to determine whether its use and function meets the redirect guidelines. Readers of this page are welcome to comment on this redirect at Wikipedia:Redirects for discussion/Log/2023 May 25 § Biomaker until a consensus is reached. Mdewman6 (talk) 21:07, 25 May 2023 (UTC)[reply]

[Neurofilament_biomarkers-1] Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, Barro C, Kappos L, Comabella M, Fazekas F, Petzold A, Blennow K, Zetterberg H, Kuhle J (October 2018). "Neurofilaments as biomarkers in neurological disorders". Nature Reviews. Neurology. 14 (10): 577–589. doi:10.1038/s41582-018-0058-z. PMID 30171200. neuroaxonal damage is the pathological substrate of permanent disability in various neurological disorders. ... Here, we review what is known about the structure and function of neurofilaments, discuss analytical aspects and knowledge of age-dependent normal ranges of neurofilaments and provide a comprehensive overview of studies on neurofilament light chain as a marker of axonal injury in different neurological disorders, including multiple sclerosis, neurodegenerative dementia, stroke, traumatic brain injury, amyotrophic lateral sclerosis and Parkinson disease.

[Prion_neurodegeneration_biomarkers-2] Thompson AB, Mead SH (December 2018). "Review: Fluid biomarkers in the human prion diseases". Molecular and Cellular Neurosciences. doi:10.1016/j.mcn.2018.12.003. PMID 30529227. The very rapid neurodegeneration of prion disease results in strong signals from surrogate protein markers in the blood that reflect neuronal, axonal, synaptic or glial pathology in the brain: notably the tau and neurofilament light chain proteins.

[1]

[2]